News

Prior to joining Aerovance, Dr Otulana worked with Aradigm, where he most recently served as senior vice president, development, and chief medical officer. Dr Otulana will provide medical

Revenue for the nine months ended December 31, 2008 increased $6.6 million, or 31%, to $28.2 million, when compared to the same period a year ago, excluding the

DX-88 is a potent and selective plasma kallikrein inhibitor, a key mediator of inflammation in angioedema, and is being evaluated as a subcutaneous therapy for treating acute HAE

Bob Odell, vice president of engineering at Cardiac Science, said: We expect considerable savings and speed-to-market improvements with Syncroness. The agreement increases Cardiac Science’s engineering capacity to manage

The reported net sales exceeded, and adjusted earnings per share for the fourth quarter and fiscal 2008 were on the high end of the guidance provided by the

Cephalon will assume all expenses for Phase III studies, regulatory filings and subsequent commercialization of the product. ImmuPharma has received a $15 million upfront fee at the initiation

During his period, Rava led the research, development and manufacturing scale-up of the Affymetrix’ GeneChip technology. He was incharge for the delivery of multiple products involving complex assays,

In the EU, Abraxane is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing

Under the terms of the agreement, the transaction includes an initial payment of $225 million plus potential additional payments contingent upon achievement of certain clinical milestones. Operating within